OverviewSuggest Edit

Plus Therapeutics (formerly known as Cytori Therapeutics) is a pharmaceutical company focused on the discovery, development, and manufacturing of treatments for patients battling cancer and other life-threatening diseases. The company delivers a range of drugs using liposomal encapsulation technology.
TypePublic
Founded1996
HQAustin, TX, US
Websiteplustherapeutics.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2020)12
Revenue (FY, 2019)$7 M(+91%)
Share Price (Jun 2021)$2.7(+6%)
Cybersecurity ratingAMore

Key People/Management at Plus Therapeutics

Marc Hedrick

Marc Hedrick

President and CEO
Andrew Sims

Andrew Sims

Vice President and Chief Financial Officer
Cheri Rice

Cheri Rice

Vice President - Product Development
Russ Havranek

Russ Havranek

Vice President - Corporate Strategy and New Product Planning
Richard Hawkins

Richard Hawkins

Chairman
Greg Petersen

Greg Petersen

Director
Show more

Plus Therapeutics Office Locations

Plus Therapeutics has offices in Austin and San Antonio
Austin, TX, US (HQ)
4200 Marathon Blvd #200
San Antonio, TX, US
12500 Network Blvd
Show all (2)

Plus Therapeutics Financials and Metrics

Plus Therapeutics Revenue

Plus Therapeutics's revenue was reported to be $7 m in FY, 2019 which is a 90.6% increase from the previous period.
USD

Net income (Q1, 2021)

(2.7m)

EBIT (Q1, 2021)

(2.5m)

Market capitalization (4-Jun-2021)

57.4m

Closing stock price (4-Jun-2021)

2.7

Cash (31-Mar-2021)

14.4m

EV

49.5m
Plus Therapeutics's current market capitalization is $57.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.4m3.7m7.0m

Revenue growth, %

(43%)91%

Cost of goods sold

1.3m1.1m

Gross profit

5.1m2.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.6m1.6m1.3m1.4m302.0k4.8m118.0k185.0k

Cost of goods sold

273.0k324.0k322.0k353.0k

Gross profit

1.4m1.2m990.0k1.1m

Gross profit Margin, %

83%79%75%75%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.6m5.3m17.6m8.3m

Accounts Receivable

145.0k286.0k1.2m

Inventories

3.2m2.9m107.0k

Current Assets

14.9m9.6m19.8m9.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

5.9m3.1m6.8m3.9m4.5m16.8m16.1m9.3m7.6m14.4m

Accounts Receivable

769.0k399.0k440.0k455.0k80.0k4.8m978.0k951.0k

Inventories

3.2m3.0m2.8m3.0m107.0k107.0k107.0k107.0k107.0k

Current Assets

10.7m7.4m10.8m8.5m5.3m22.3m17.7m10.8m8.6m15.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.7m)(12.6m)(10.9m)(8.2m)

Depreciation and Amortization

2.2m2.0m896.0k366.0k

Inventories

251.0k475.0k259.0k

Accounts Payable

(1.8m)(1.5m)(28.0k)(1.2m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(4.4m)(8.1m)(10.4m)(3.1m)(12.3m)(11.8m)(1.1m)(2.9m)(4.7m)(2.7m)

Depreciation and Amortization

497.0k975.0k1.5m443.0k617.0k778.0k94.0k188.0k273.0k88.0k

Inventories

141.0k371.0k615.0k16.0k235.0k274.0k

Accounts Payable

(556.0k)(1.2m)(1.3m)(405.0k)(94.0k)(95.0k)410.0k371.0k(1.6m)(461.0k)
USDFY, 2017

Revenue/Employee

173.3k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.4 x
Show all financial metrics

Plus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Plus Therapeutics Online and Social Media Presence

Embed Graph

Plus Therapeutics News and Updates

Thinking about buying stock in Plus Therapeutics, AMC Entertainment, ProQR Therapeutics, Nokia, or Diana Shipping?

NEW YORK, May 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, AMC, PRQR, NOK, and DSX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements

– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply

Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021…

Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets

Plus Therapeutics to Participate in Upcoming Virtual Conferences

AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Off…

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –
Show more

Plus Therapeutics Frequently Asked Questions

  • When was Plus Therapeutics founded?

    Plus Therapeutics was founded in 1996.

  • Who are Plus Therapeutics key executives?

    Plus Therapeutics's key executives are Marc Hedrick, Andrew Sims and Cheri Rice.

  • How many employees does Plus Therapeutics have?

    Plus Therapeutics has 12 employees.

  • Who are Plus Therapeutics competitors?

    Competitors of Plus Therapeutics include Praedicare Labs, Allogene Therapeutics and AVEO Pharmaceuticals.

  • Where is Plus Therapeutics headquarters?

    Plus Therapeutics headquarters is located at 4200 Marathon Blvd #200, Austin.

  • Where are Plus Therapeutics offices?

    Plus Therapeutics has offices in Austin and San Antonio.

  • How many offices does Plus Therapeutics have?

    Plus Therapeutics has 2 offices.